Malin Sund retweetledi

Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
➡️ doi.org/10.1093/bjs/zn…
📊 Individual patient data from 7 phase III RCTs (n=1,044 ESCC patients, 6 countries)
💊 NAC vs 🔥 NACRT → pCR rates: 6.9% vs 34.2%
🔎 Among patients achieving pCR (n=192):
• 5-year OS: 97.5% (NAC) vs 70.4% (NACRT)
• 5-year RFS: 80.8% (NAC) vs 63.7% (NACRT)
📈 Multivariable analysis confirmed a significant survival advantage for NAC in the pCR subgroup
🎯 Take-home: pCR is not biologically equivalent across modalities. ESCC patients achieving pCR after NAC have an exceptionally favourable prognosis—raising the question of whether this group could be considered for future surgery-avoidance or watch-and-wait strategies.
Work by Jun Okui , Satoru Matsuda , Kengo Nagashima , Yasunori Sato , Hirofumi Kawakubo , Thomas Ruhstaller , Peter Thuss-Patience , Magnus Nilsson , Fredrik Klevebro , Lijie Tan , Shaoyuan Zhang , Thomas Aparicio , Guillaume Piessen , Charlène van der Zijden , Bianca Mostert , Bas P L Wijnhoven , Takahiro Tsushima , Hiroya Takeuchi , Ken Kato , Yuko Kitagawa
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide #some4UGI #uppergi #esophagealcancer #gastriccancer #reflux @ISDE_net @Augishealth @roux_group @T4UGIS @SARONG_Trial @YoungIFSO #bariatricsurgery

English























